This is an aggregated industry headline. Read the full story at FiercePharma →
Novo's success with oral Wegovy has been fueled by 'familiarity': Spherix
Name recognition and "familiarity" with Novo Nordisk's oral Wegovy has contributed to its rapid uptake in its battle with Lilly's oral GLP-1 Foundayo, according to Spherix analyst Jim Hickey, who conducts monthly surveys with doctors who prescribe the treatments.
By FiercePharma
· Jun 21, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
In another biotech born out of China's "NewCo" model, cAMPfield Therapeutics has launched with a $180 million …
The WeekBriefing
With pharma M&A and IPOs accelerating, unprepared companies risk missing out as investors demand speed, clean …
The WeekAJMC ↗
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently…